UNICREDIT BANK/CALL/ROCHE GS/280/0.1/19.03.25 Stock

Warrant

DE000HD43M11

Market Closed - Bid/Ask 01:24:28 2024-07-16 pm EDT After market 02:00:10 pm
0.94 EUR +8.05% Intraday chart for UNICREDIT BANK/CALL/ROCHE GS/280/0.1/19.03.25 0.965 +2.66%
Current month+29.85%
1 month+26.09%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-16 0.94 +8.05%
24-07-15 0.87 +8.75%
24-07-12 0.8 +14.29%
24-07-11 0.7 +7.69%
24-07-10 0.65 +22.64%

Delayed Quote Börse Stuttgart

Last update July 16, 2024 at 01:24 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer UniCredit UniCredit
WKN HD43M1
ISINDE000HD43M11
Date issued 2024-03-25
Strike 280 CHF
Maturity 2025-03-19 (246 Days)
Parity 10 : 1
Emission price 0.49
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.94
Lowest since issue 0.2
Spread 0.04
Spread %4.08%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
258.7 CHF
Average target price
274 CHF
Spread / Average Target
+5.91%
Consensus